FT576 in Subjects With Multiple Myeloma
Is a
Allocation Type
Non-Randomized
0
Participating Facility
Health Conditions in Trial
Intervention Model
Parallel Assignment
0
Intervention Name
FT576 (Allogenic CAR NK cells with BCMA expression)
0
Cyclophosphamide
0
Fludarabine
0
Daratumumab
0
Bendamustine
0
Interventional Trial Phase
Phase 1
0
Interventional Trial Purpose
Treatment
0
Intervention Type
Drug
0
Last Updated
May 3, 2023
0
Masking Type
None (Open Label)
0
Primary Completion Date
2024
0
Trial Recruitment Size
168
0
Trial Sponsor
Clinical Trial Start Date
November 24, 2021
0
Study Completion Date
2040
0
Clinical Trial Study Type
Interventional
0
NCT Number
Official Name
A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma
0
Official Website
Find more entities like FT576 in Subjects With Multiple Myeloma
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.